News

Horizon Pharma bags Hyperion in US$1.1bn deal
Enlarge image

M&AIreland

Horizon Pharma bags Hyperion in US$1.1bn deal

31.03.2015 - In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

Horizon will take on two treatments from Hyperion’s portfolio for a rare metabolic condition. “The Hyperion acquisition will expand and diversify our product portfolio by adding two complementary orphan disease products, Ravicti and Buphenyl, and leverage as well as expand the existing infrastructure of our orphan disease business,” Horizon Chief Executive Timothy P. Walbert said. Ravicti and Buphenyl are medicines used to treat Urea Cycle Disorders (UCD). 

Orphan diseases, also known as rare diseases, are rare conditions that affect a small percentage of the population, i.e. less than 5 in 10,000 people. According to the EU, the number of persons in Europe suffering from a rare disease is estimated at over 30 million. The pharmaceutical industry are often reluctant to tackle these conditions as there is little financial incentive to develop treatments.

The deal has been approved by both boards and is expected to close in the second quarter of 2015. The Hyperion deal furthers Horizon Pharma’s business operations in the US. In 2014, the Irish company bought the US rights to AstraZeneca’s Vimovo delayed-release tablets for osteoarthritis and rheumatoid arthritis.

© european-biotechnology-news.com/jc

http://www.european-biotechnology-news.com/news/news/2015-01/horizon-pharma-bags-hyperion-inus11bndeal.html

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON27.83 EUR3.30%
  • EVONIK34.17 EUR2.92%
  • VITA 345.91 EUR1.55%

FLOP

  • EPIGENOMICS5.59 EUR-5.73%
  • WILEX2.86 EUR-4.98%
  • BB BIOTECH271.10 EUR-4.88%

TOP

  • CYTOS1.43 CHF297.2%
  • MEDIGENE12.33 EUR184.8%
  • FORMYCON27.83 EUR71.5%

FLOP

  • MORPHOSYS57.18 EUR-21.9%
  • WILEX2.86 EUR-9.2%
  • BASILEA110.70 CHF-7.8%

TOP

  • SANTHERA93.75 CHF2186.6%
  • FORMYCON27.83 EUR283.9%
  • WILEX2.86 EUR144.4%

FLOP

  • CYTOS1.43 CHF-53.1%
  • MOLOGEN5.41 EUR-52.9%
  • PAION2.35 EUR-36.0%

No liability assumed, Date: 01.04.2015